This review compares the risks of continuing GLP-1 receptor agonists long-term against the risks of discontinuation, addressing a critical clinical question as these drugs are often prescribed only for limited periods.
Discontinuation reverses benefitsGLP-1RAs are often prescribed for limited periods, but stopping therapy typically leads to weight regain and loss of cardiovascular and metabolic improvements
What the researchers found
GLP-1 receptor agonists have become first-line therapy for multiple clinical settings based on strong scientific evidence for obesity, type 2 diabetes, hypertension, heart failure, and cardiovascular disease. However, concerns about long-term adverse effects lead clinicians to prescribe them for limited periods, often discontinuing once weight reduction is achieved. The review examines evidence comparing the risks of long-term GLP-1RA use (potential adverse effects) against the risks of discontinuation (weight regain, loss of cardiovascular and metabolic benefits).
Why it matters
This is one of the most important unanswered questions in obesity medicine today. Tens of millions of people are now on GLP-1 receptor agonists, and many face the decision of whether to continue indefinitely or stop after achieving weight loss. The evidence suggests that discontinuation reverses many benefits, but concerns about unknown long-term effects create clinical uncertainty. This review helps frame the risk-benefit calculation.
How the study worked
Narrative literature review examining clinical effects and indications of GLP-1 receptor agonists, with a focus on comparing long-term safety data against the consequences of treatment discontinuation. Published in a cardiology journal, reflecting the cardiovascular perspective on this question.
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. Long-term safety data for GLP-1RAs beyond 2-5 years is limited, making definitive conclusions about very long-term risks difficult. The review focuses on the risk comparison framework but may not cover all emerging safety signals. Individual patient factors affecting the risk-benefit balance are not addressed in detail.
How to read the evidence
This is a narrative review published in Current Problems in Cardiology. It synthesizes existing clinical trial and real-world evidence but does not present new data. The underlying evidence base for long-term GLP-1RA safety is still maturing.
When this study was published
Published in 2026, this is a very current review addressing one of the most pressing questions in obesity and cardiovascular medicine as GLP-1RA use reaches unprecedented levels.
The bigger picture
The GLP-1RA discontinuation question mirrors the broader challenge of treating obesity as a chronic disease. Just as hypertension medications are typically lifelong, the evidence increasingly suggests that obesity pharmacotherapy may need to be as well. This has enormous implications for healthcare costs, drug supply chains, and patient expectations — making the risk-benefit analysis of long-term use critically important.
Questions still open
- What is the optimal duration of GLP-1RA therapy for patients who achieve their weight loss goals — is lifelong treatment necessary?
- Are there strategies to mitigate weight regain after GLP-1RA discontinuation, such as dose reduction or intermittent use?
- Will 10+ years of real-world data reveal long-term safety concerns not captured in current clinical trials?
Common questions
What happens when you stop taking a GLP-1 receptor agonist?
Are there serious risks to taking GLP-1 agonists long-term?
Read the original research
GLP1-RAs: long-term use versus discontinuation events of an emerging therapy for obesity and cardiovascular diseases.
Current problems in cardiology, 51(2), 103213
Citation
Salerno, Elia Nunzio Maria; Fumarulo, Isabella; Garramone, Barbara; Vaccarella, Marcello; Ierardi, Carolina; Burzotta, Francesco; Aspromonte, Nadia. (2026). GLP1-RAs: long-term use versus discontinuation events of an emerging therapy for obesity and cardiovascular diseases.. Current problems in cardiology, 51(2), 103213. https://doi.org/10.1016/j.cpcardiol.2025.103213